British drugmaker AstraZeneca topped second-quarter sales and profit estimates and backed the company’s 2020 forecasts, helped by strong sales in lockdowns of a diverse product range that includes a potential coronavirus vaccine.

Pfizer Inc. filed a lawsuit seeking to require the federal government to let it help Medicare beneficiaries afford two drugs to treat a rare and sometimes fatal heart condition, and which cost $225,000 a year.